Published in J Clin Pharm Ther on April 01, 2005
Impact of a statewide Internet-based tobacco cessation intervention. J Med Internet Res (2007) 1.61
Patterns of medical pluralism among adults: results from the 2001 National Health Interview Survey in Taiwan. BMC Health Serv Res (2010) 1.05
Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study. BMC Neurol (2008) 0.87
Tobacco control and nicotine addiction in Canada: current trends, management and challenges. Can Respir J (2009) 0.80
Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol (1985) 5.00
Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen. J Cell Biol (1987) 4.50
CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell (1992) 3.70
Immunolocalization of CENP-A suggests a distinct nucleosome structure at the inner kinetochore plate of active centromeres. Curr Biol (1997) 3.62
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology (2007) 3.17
CENP-C is required for maintaining proper kinetochore size and for a timely transition to anaphase. J Cell Biol (1994) 2.86
Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. J Cell Biol (1993) 2.48
The hBUB1 and hBUBR1 kinases sequentially assemble onto kinetochores during prophase with hBUBR1 concentrating at the kinetochore plates in mitosis. Chromosoma (1998) 2.18
Analysis of the distribution of the INCENPs throughout mitosis reveals the existence of a pathway of structural changes in the chromosomes during metaphase and early events in cleavage furrow formation. J Cell Sci (1991) 1.81
Structure of the human centromere at metaphase. Trends Biochem Sci (1990) 1.74
Role of the centromere/kinetochore in cell cycle control. Cold Spring Harb Symp Quant Biol (1991) 1.52
Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Mult Scler (2009) 1.52
A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry (2005) 1.50
Silicone oil migration causing increasing proptosis 13 years after retinal surgery. Eye (Lond) (2006) 1.44
Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother (1995) 1.41
Compartmentalization within the nucleus: discovery of a novel subnuclear region. J Cell Biol (1991) 1.37
A poison education program for primary school. Vet Hum Toxicol (1984) 1.27
Direct and indirect association of the small GTPase ran with nuclear pore proteins and soluble transport factors: studies in Xenopus laevis egg extracts. Mol Biol Cell (1996) 1.25
Proteins of the inner and outer centromere of mitotic chromosomes. Genome (1989) 1.08
Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution. J Cell Biol (1998) 1.03
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care (2000) 0.95
Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther (2002) 0.91
An atypical presentation of Wernicke's encephalopathy in an 11-year-old child. Eye (Lond) (2006) 0.82
Impact of a limited fluoroquinolone reimbursement policy on antimicrobial prescription claims. Ann Pharmacother (2001) 0.81
Renal transplantation in secondary oxalosis. Transplantation (1988) 0.79
Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey. Can J Cardiol (1999) 0.79
The pharmacokinetics of trichlormethiazide in hypertensive patients with normal and compromised renal function. Eur J Clin Pharmacol (1981) 0.76
Erythromycin-cyclosporin interaction. Drug Intell Clin Pharm (1986) 0.75
Is there a problem with benzodiazepine prescribing in maritime Canada? Can Fam Physician (1985) 0.75
How effective are disease-modifying drugs in delaying progression in relapsing-onset ms? Neurology (2008) 0.75
Tacrolimus in transplantation. Am J Health Syst Pharm (1995) 0.75
Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. J Clin Pharmacol (1982) 0.75
Ipecac syrup for poisonings at home: availability, compliance, and response monitored by telephone. Am J Hosp Pharm (1981) 0.75
Effect of coadministration of acyclovir and cyclosporine on kidney function and cyclosporine concentrations in renal transplant patients. DICP (1991) 0.75
Cyclosporine absorption in two patients with short-bowel syndrome. Drug Intell Clin Pharm (1988) 0.75
Community awareness of the Poison Control Centre and ipecac syrup. Can J Public Health (1983) 0.75
Economic status of callers to a poison center. Am J Hosp Pharm (1981) 0.75
A closer look at anterior segment intraocular foreign bodies. Eye (Lond) (2005) 0.75
Concordance with a STOPP (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) Criterion in Nova Scotia, Canada: Benzodiazepine and Zoplicone Prescription Claims by Older Adults with Fall-related Hospitalizaions. J Popul Ther Clin Pharmacol (2016) 0.75
Increased cyclosporine bioavailability from a microemulsion formulation in a liver transplant recipient. Ann Pharmacother (1994) 0.75
Compliance with guidelines for monitoring aminoglycoside therapy. Can J Hosp Pharm (1983) 0.75
Methods of controlling cephalosporin use in Canadian hospitals. Can J Hosp Pharm (1988) 0.75
Halothane hepatitis in a renal transplant patient previously exposed to isoflurane. Ann Pharmacother (1993) 0.75
Effect of vitamin C on the excretion of methotrexate. Cancer Treat Rep (1984) 0.75